A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Seagen Inc.
Pfizer
Eli Lilly and Company
AstraZeneca
Pfizer
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AbbVie
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Parabilis Medicines, Inc.
Seagen Inc.
Summit Therapeutics
Novartis
Ono Pharmaceutical Co., Ltd.
EMD Serono
Multitude Therapeutics Inc.
Pfizer
Akeso
Seagen Inc.
AstraZeneca
Luye Pharma Group Ltd.
Bold Therapeutics, Inc.
Merck Sharp & Dohme LLC
GlaxoSmithKline
Tyligand Pharmaceuticals (Suzhou) Limited
Enliven Therapeutics
Akeso
Bristol-Myers Squibb
Bristol-Myers Squibb
Jazz Pharmaceuticals
Pfizer
Incyte Corporation
Toray Industries, Inc
Gilead Sciences
Taizhou Mabtech Pharmaceutical Co.,Ltd
Seattle Project Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pierre Fabre Medicament
IGM Biosciences, Inc.
ImmunityBio, Inc.
Hansoh BioMedical R&D Company
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Ono Pharmaceutical Co., Ltd.